Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,311–1,320 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1311
- Medicine slug
- rasagiline
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 0.882353
- Recorded readings
88 to 94%
- Numeric value
- 88
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dfeec8f-f4f3-4e06-915e-3244467516a6 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e802c83c-e581-4a11-b83d-1df47120078d (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a40d0e73-3f9f-4b01-979d-402c9cdaeb60 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9168d62-814a-444f-9d70-11674def339d (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e84da5ee-f93a-4e0e-9120-7dfcb9d18430 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ee5cc48-7e1e-b268-e063-6394a90a5629 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8771c7e-5ecf-47dc-a0fd-4d12e85631a6 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a62a9946-755f-47d0-afe6-edc8f7d641fe (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b57a1c9-0ad9-40cf-a972-29851a658489 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bf8e76c-27cb-42a4-aa9c-bdade68c463b (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4f5042-0e21-40a0-8352-bb28bb752bfa (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdebcedc-1b5e-4803-9617-58d705cda726 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42f8d62f-2c57-47bc-92e7-b28111aa8cd1 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c5e3cde-1158-4b5a-9a2b-ea6c987a65e4 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bf059f4-4da8-48fe-aacb-c50717d36606 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88 to 94% with mean extent of binding of 61 to 63% to human albumin over the concentration range of 1 to 100 ng/mL.
88%
- Numeric value
- 88
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c234b28-29e7-4149-9505-e2818a692bca (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88% to 94% with mean extent of binding of 61% to 63% to human albumin over the concentration range of 1 ng/mL to 100 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d9eac3f-7441-45cf-a603-ea18c116e2c0 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Plasma protein binding ranges from 88% to 94% with mean extent of binding of 61% to 63% to human albumin over the concentration range of 1 ng/mL to 100 ng/mL.
Projected row 1312
- Medicine slug
- rasagiline
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dfeec8f-f4f3-4e06-915e-3244467516a6 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c234b28-29e7-4149-9505-e2818a692bca (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e802c83c-e581-4a11-b83d-1df47120078d (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (Cmax) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a40d0e73-3f9f-4b01-979d-402c9cdaeb60 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (Cmax) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9168d62-814a-444f-9d70-11674def339d (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e84da5ee-f93a-4e0e-9120-7dfcb9d18430 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ee5cc48-7e1e-b268-e063-6394a90a5629 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d9eac3f-7441-45cf-a603-ea18c116e2c0 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8771c7e-5ecf-47dc-a0fd-4d12e85631a6 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a62a9946-755f-47d0-afe6-edc8f7d641fe (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b57a1c9-0ad9-40cf-a972-29851a658489 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (Cmax) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bf8e76c-27cb-42a4-aa9c-bdade68c463b (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4f5042-0e21-40a0-8352-bb28bb752bfa (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdebcedc-1b5e-4803-9617-58d705cda726 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42f8d62f-2c57-47bc-92e7-b28111aa8cd1 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c5e3cde-1158-4b5a-9a2b-ea6c987a65e4 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bf059f4-4da8-48fe-aacb-c50717d36606 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Absorption Rasagiline is rapidly absorbed, reaching peak plasma concentration (C max ) in approximately 1 hour.
Projected row 1313
- Medicine slug
- rasagiline
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
87 L
- Numeric value
- 87
- Unit
- L
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dfeec8f-f4f3-4e06-915e-3244467516a6 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c234b28-29e7-4149-9505-e2818a692bca (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e802c83c-e581-4a11-b83d-1df47120078d (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a40d0e73-3f9f-4b01-979d-402c9cdaeb60 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9168d62-814a-444f-9d70-11674def339d (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e84da5ee-f93a-4e0e-9120-7dfcb9d18430 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ee5cc48-7e1e-b268-e063-6394a90a5629 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d9eac3f-7441-45cf-a603-ea18c116e2c0 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8771c7e-5ecf-47dc-a0fd-4d12e85631a6 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a62a9946-755f-47d0-afe6-edc8f7d641fe (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b57a1c9-0ad9-40cf-a972-29851a658489 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bf8e76c-27cb-42a4-aa9c-bdade68c463b (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4f5042-0e21-40a0-8352-bb28bb752bfa (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdebcedc-1b5e-4803-9617-58d705cda726 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42f8d62f-2c57-47bc-92e7-b28111aa8cd1 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c5e3cde-1158-4b5a-9a2b-ea6c987a65e4 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bf059f4-4da8-48fe-aacb-c50717d36606 (opens source in a new tab)
Rasagiline label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state is 87 L, indicating that the tissue binding of rasagiline is in excess of plasma protein binding.
Projected row 1314
- Medicine slug
- regadenoson
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88909dc6-502a-61b1-b8e1-22a42da65847 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology ( 12.2 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af131207-097f-3901-e711-fba004944076 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology ( 12.2 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:843bfba9-47de-4d76-843a-997bb4564f6e (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology ( 12.2 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ef6420-8190-a404-f7f6-def1864a77de (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [see Clinical Pharmacology ( 12.2) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a550b451-fb30-4c1c-a60e-6e40fba20c88 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [see Clinical Pharmacology ( 12.2 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:057289f4-2e18-4c1e-bed4-6c1858e2ef16 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology ( 12.2 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e4109f0-4875-4f8e-b70d-4055b3a785a3 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [see Clinical Pharmacology (12.2)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288c76cc-ff3e-47ea-ae02-be566bd3e093 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology ( 12.2 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5095ab40-8503-46db-9b08-6a36f05fb5d9 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology ( 12.2 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e3f080d-b1fb-47ed-8cd3-90a4206fa704 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [see Clinical Pharmacology (12.2) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b183399d-b8dc-4924-90cd-a1c2247742f3 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology ( 12.2 ) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81d66a7-b714-439e-ad7b-c7caf9d6f3b8 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology (12.2) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e48b407-1ce3-461d-b48e-de183802de25 (opens source in a new tab)
Regadenoson label
Version not recorded · Effective date not recorded
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [ see Clinical Pharmacology (12.2) ].
Projected row 1315
- Medicine slug
- remifentanil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2374b84-81c9-44f9-a4a9-1071281b2531 (opens source in a new tab)
Remifentanil label
Version not recorded · Effective date not recorded
This is similar to the 3- to 10-minute half-life measured after termination of prolonged infusions (up to 4 hours; see Figure 2) and correlates with recovery times observed in the clinical setting after infusions up to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b8025d2-3424-477b-9cff-3990a98c2a65 (opens source in a new tab)
Remifentanil label
Version not recorded · Effective date not recorded
This is similar to the 3- to 10-minute half-life measured after termination of prolonged infusions (up to 4 hours; see Figure 2) and correlates with recovery times observed in the clinical setting after infusions up to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b4c8696-e23e-4c51-a4d2-babab5bd945a (opens source in a new tab)
Remifentanil label
Version not recorded · Effective date not recorded
This is similar to the 3- to 10-minute half-life measured after termination of prolonged infusions (up to 4 hours; see Figure 2) and correlates with recovery times observed in the clinical setting after infusions up to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d289052-1eb6-4ba2-a3ca-d2e542a052ae (opens source in a new tab)
Remifentanil label
Version not recorded · Effective date not recorded
This is similar to the 3- to 10- minute half-life measured after termination of prolonged infusions (up to 4 hours; see Figure 2) and correlates with recovery times observed in the clinical setting after infusions up to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4dbcb8f9-1987-4b66-bd2f-d251fda0be10 (opens source in a new tab)
Remifentanil label
Version not recorded · Effective date not recorded
This is similar to the 3- to 10-minute half-life measured after termination of prolonged infusions (up to 4 hours; see Figure 2) and correlates with recovery times observed in the clinical setting after infusions up to 12 hours.
Projected row 1316
- Medicine slug
- repaglinide
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
56%
- Numeric value
- 56
- Unit
- %
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7673e22-0dbb-4395-ad60-943d249203a1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f3118ce-fcbb-4f8b-b1ba-d8cd95e5b665 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68064989-47ea-4ed5-a20e-43c4ef6ec271 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b150917-e2fd-4366-af83-ebc1d7297ca9 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ae28683-28cc-408e-90f9-6a3dddfc668d (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd1d8337-9903-4b8a-a9ea-569e4d134e74 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a93246c-9323-40c4-b590-a40dcb133c8c (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb995e92-295e-4638-a064-978211f5afe1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f2006d9-e0c0-4cc4-b2c9-84b7d9f77173 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d85abce4-16da-4231-b28a-6afca04ebf68 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
The mean absolute bioavailability is 56%.
Projected row 1317
- Medicine slug
- repaglinide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7673e22-0dbb-4395-ad60-943d249203a1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f3118ce-fcbb-4f8b-b1ba-d8cd95e5b665 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68064989-47ea-4ed5-a20e-43c4ef6ec271 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b150917-e2fd-4366-af83-ebc1d7297ca9 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ae28683-28cc-408e-90f9-6a3dddfc668d (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd1d8337-9903-4b8a-a9ea-569e4d134e74 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a93246c-9323-40c4-b590-a40dcb133c8c (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb995e92-295e-4638-a064-978211f5afe1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f2006d9-e0c0-4cc4-b2c9-84b7d9f77173 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d85abce4-16da-4231-b28a-6afca04ebf68 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour.
Projected row 1318
- Medicine slug
- repaglinide
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7673e22-0dbb-4395-ad60-943d249203a1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f3118ce-fcbb-4f8b-b1ba-d8cd95e5b665 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68064989-47ea-4ed5-a20e-43c4ef6ec271 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b150917-e2fd-4366-af83-ebc1d7297ca9 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ae28683-28cc-408e-90f9-6a3dddfc668d (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd1d8337-9903-4b8a-a9ea-569e4d134e74 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a93246c-9323-40c4-b590-a40dcb133c8c (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb995e92-295e-4638-a064-978211f5afe1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f2006d9-e0c0-4cc4-b2c9-84b7d9f77173 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d85abce4-16da-4231-b28a-6afca04ebf68 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Protein binding and binding to human serum albumin was greater than 98%.
Projected row 1319
- Medicine slug
- repaglinide
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
31 L
- Numeric value
- 31
- Unit
- L
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7673e22-0dbb-4395-ad60-943d249203a1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f3118ce-fcbb-4f8b-b1ba-d8cd95e5b665 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68064989-47ea-4ed5-a20e-43c4ef6ec271 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b150917-e2fd-4366-af83-ebc1d7297ca9 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ae28683-28cc-408e-90f9-6a3dddfc668d (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd1d8337-9903-4b8a-a9ea-569e4d134e74 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a93246c-9323-40c4-b590-a40dcb133c8c (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb995e92-295e-4638-a064-978211f5afe1 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f2006d9-e0c0-4cc4-b2c9-84b7d9f77173 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d85abce4-16da-4231-b28a-6afca04ebf68 (opens source in a new tab)
Repaglinide label
Version not recorded · Effective date not recorded
Distribution After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ss ) was 31 L, and the total body clearance (CL) was 38 L/h.
Projected row 1320
- Medicine slug
- ribavirin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
9.5 hours
- Numeric value
- 9.5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3631ee95-692a-4426-8edf-62c27f7c32cb (opens source in a new tab)
Ribavirin label
Version not recorded · Effective date not recorded
The plasma half-life was reported to be 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d74aa4f3-0b7d-480d-b5bf-41ddf808b260 (opens source in a new tab)
Ribavirin label
Version not recorded · Effective date not recorded
The plasma half-life was reported to be 9.5 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1310Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.